AU2003290432A8 - T cell activating gene - Google Patents

T cell activating gene

Info

Publication number
AU2003290432A8
AU2003290432A8 AU2003290432A AU2003290432A AU2003290432A8 AU 2003290432 A8 AU2003290432 A8 AU 2003290432A8 AU 2003290432 A AU2003290432 A AU 2003290432A AU 2003290432 A AU2003290432 A AU 2003290432A AU 2003290432 A8 AU2003290432 A8 AU 2003290432A8
Authority
AU
Australia
Prior art keywords
cell activating
activating gene
gene
cell
activating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003290432A
Other versions
AU2003290432A1 (en
Inventor
Shiho Yoneta
Akio Matsuda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Asahi Kasei Pharma Corp
Original Assignee
Asahi Kasei Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asahi Kasei Pharma Corp filed Critical Asahi Kasei Pharma Corp
Publication of AU2003290432A8 publication Critical patent/AU2003290432A8/en
Publication of AU2003290432A1 publication Critical patent/AU2003290432A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
AU2003290432A 2002-12-26 2003-12-25 T cell activating gene Abandoned AU2003290432A1 (en)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
JP2002-376365 2002-12-26
JP2002376365 2002-12-26
US43647302P 2002-12-27 2002-12-27
US60/436,473 2002-12-27
JP2003-122113 2003-04-25
JP2003122113 2003-04-25
US46579203P 2003-04-28 2003-04-28
US60/465,792 2003-04-28
JP2003360559 2003-10-21
JP2003-360559 2003-10-21
US51284603P 2003-10-22 2003-10-22
US60/512,846 2003-10-22
PCT/JP2003/016715 WO2004058805A2 (en) 2002-12-26 2003-12-25 T cell activating gene

Publications (2)

Publication Number Publication Date
AU2003290432A8 true AU2003290432A8 (en) 2004-07-22
AU2003290432A1 AU2003290432A1 (en) 2004-07-22

Family

ID=32686376

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003290432A Abandoned AU2003290432A1 (en) 2002-12-26 2003-12-25 T cell activating gene

Country Status (2)

Country Link
AU (1) AU2003290432A1 (en)
WO (1) WO2004058805A2 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003256106A1 (en) * 2002-08-14 2004-03-03 Lg Life Sciences Ltd. Gene families associated with liver cancer
US7332282B2 (en) 2003-08-19 2008-02-19 The Regents Of The University Of Michigan Compositions and methods for detecting and treating neurological conditions
WO2005095447A2 (en) * 2004-03-29 2005-10-13 Isis Innovation Limited Low molecular weight forms of foxp1 proteins and splice variants thereof
EP1733743A4 (en) * 2004-04-09 2007-06-27 Takeda Pharmaceutical Preventives/remedies for cancer
US7485468B2 (en) * 2004-10-15 2009-02-03 Galapagos Bv Molecular targets and compounds, and methods to identify the same, useful in the treatment of joint degenerative and inflammatory diseases
US8673268B2 (en) 2004-10-15 2014-03-18 Galapagos N.V. Molecular targets and compounds, and methods to identify the same, useful in the treatment of joint degenerative and inflammatory diseases
JP2006273760A (en) * 2005-03-29 2006-10-12 Sony Corp RORalpha PROMOTING EXPRESSION INDUCEMENT OF BMAL1
RU2450019C2 (en) * 2006-06-29 2012-05-10 Новартис Аг Neisseria meningitidis polypeptides
JP6095889B2 (en) * 2008-05-16 2017-03-15 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアＴｈｅ Ｃｈｉｌｄｒｅｎ’Ｓ Ｈｏｓｐｉｔａｌ Ｏｆ Ｐｈｉｌａｄｅｌｐｈｉａ Chromosome 21q, 6q, and 15q gene mutations and methods for using them to diagnose and treat type 1 diabetes
WO2013063019A1 (en) 2011-10-28 2013-05-02 The Wistar Institute Of Anatomy And Biology Methods and compositions for enhancing the therapeutic effect of anti-tumor t cells
EP2799542A4 (en) * 2011-12-29 2015-07-01 Tao Health Life Pharma Co Ltd Target molecule to which amylospheroid binds and induces mature neuronal cell death, method and substance for inhibiting amylospheroid-induced neuronal cell death, and uses for said target molecule, method, and substance
US20150118257A1 (en) * 2012-04-20 2015-04-30 The Wistar Institute Of Anatomy And Biology Methods and Compositions for Manipulating the Immune System
US20170157243A1 (en) * 2014-06-24 2017-06-08 University Of Massachusetts MANF as a Regulator of Immune System Function
HUE049032T2 (en) 2015-02-19 2020-08-28 Compugen Ltd Anti-pvrig antibodies and methods of use
WO2016134335A2 (en) * 2015-02-19 2016-08-25 Compugen Ltd. Pvrig polypeptides and methods of treatment
MY194032A (en) 2016-08-17 2022-11-09 Compugen Ltd Anti-tigit antibodies, anti-pvrig antibodies and combinations thereof
GB201615844D0 (en) * 2016-09-16 2016-11-02 Genagon Therapeutics Ab Agents for use in therapy
GB201700567D0 (en) 2017-01-12 2017-03-01 Genagon Therapeutics Ab Therapeutic agents
AU2018276140A1 (en) 2017-06-01 2019-12-19 Compugen Ltd. Triple combination antibody therapies
CN112584865A (en) 2018-07-20 2021-03-30 表面肿瘤学公司 anti-CD 112R compositions and methods
EP3715848A1 (en) * 2019-03-25 2020-09-30 Université de Bretagne Occidentale (U.B.O.) Substance interacting with c terminal fragment of the stim1 fraction localized to the plasma membrane of the cells, for its use in the treatment of cancers, and in screening and diagnostic methods

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1354950A4 (en) * 2000-12-28 2005-01-12 Asahi Kasei Pharma Corp Nf-kb activating gene
EP1293569A3 (en) * 2001-09-14 2004-03-31 Research Association for Biotechnology Full-length cDNAs
AU2002349784A1 (en) * 2001-12-03 2003-06-17 Asahi Kasei Pharma Corporation Nf-kappab activating genes

Also Published As

Publication number Publication date
WO2004058805A3 (en) 2004-11-04
AU2003290432A1 (en) 2004-07-22
WO2004058805A2 (en) 2004-07-15

Similar Documents

Publication Publication Date Title
HK1181815A1 (en) Cells with modified genome
AU2003265826A8 (en) Electrolyte
AU2003290432A8 (en) T cell activating gene
EP1989528A4 (en) Cell tray
AU2003260351A8 (en) Cell culture insert
TWI369020B (en) Electrochemical cell
GB2404665B (en) Cell culture
GB2386955B (en) Electrochemical Cell
EP1519543A4 (en) Cell phone
PL374671A1 (en) Electrochemical cell
GB0206357D0 (en) Cells
ZA200506732B (en) Cell culture
GB2422843B (en) Cell culture base
GB0227705D0 (en) Electrochemical cell
GB0407620D0 (en) Cell lines
AU2003294705A8 (en) Ntsm gene
ZA200501352B (en) Cell culture surface
GB0206309D0 (en) Isolated cells
SG102044A1 (en) Cell culture system
PL376397A1 (en) Transplantable cell
IL158173A0 (en) Nanopatch-containing cells
GB0217533D0 (en) Cell culture
GB0219777D0 (en) Cell culture
GB0210458D0 (en) Cell culture
GB0226482D0 (en) Elecrochemical cell

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase